melphalan,sacituzumab,fludarabine,busulfan
otsuka,Bayer,gilead,gsk
['leukemia', ' sg ', 'myeloid', 'fludarabine', 'lymphoma', 'melphalan', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders),(-dreamlike)', 'mds', 'busulfan']
#ash22 #bmtsm holtan: median age 66 in both arms. ~50% aml and ~30% mds in both arms. balanced donor sources (~30% sibs and ~70% mud). 1yr grfs 52.7% w ptcy vs 34.9% w tac/mtx w 2-fold reduction in severe agvhd and cgvhd and no differences in relapse. 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)